Sphera Funds Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.25M Buy
+10,800
New +$3.26M 0.42% 77
2024
Q4
Sell
-7,000
Closed -$1.93M 111
2024
Q3
$1.93M Buy
+7,000
New +$1.82M 0.31% 86
2024
Q1
Sell
-36,230
Closed -$6.04M 105
2023
Q4
$6.93M Buy
36,230
+129
+0.4% +$22K 1.12% 33
2023
Q3
$6.39M Sell
36,101
-3,899
-10% -$744K 1.16% 29
2023
Q2
$7.6M Buy
+40,000
New +$7.93M 1.19% 24
2022
Q2
Sell
-24,768
Closed -$3.51M 59
2022
Q1
$4.04M Buy
+24,768
New +$3.77M 0.57% 42
2018
Q4
Sell
-40,000
Closed -$3.5M 103
2018
Q3
$3.5M Sell
40,000
-155,232
-80% -$15.6M 0.4% 74
2018
Q2
$19.2M Buy
+195,232
New +$19.4M 2.65% 9
2017
Q3
Sell
-50,000
Closed -$3.99M 132
2017
Q2
$3.99M Buy
+50,000
New +$3.2M 0.68% 46
2016
Q2
Sell
-70,000
Closed -$4.41M 95
2016
Q1
$4.39M Buy
70,000
+30,000
+75% +$1.99M 0.95% 16
2015
Q4
$3.77M Hold
40,000
0.55% 33
2015
Q3
$3.21M Buy
40,000
+3,000
+8% +$333K 0.41% 51
2015
Q2
$4.43M Buy
+37,000
New +$4.42M 0.43% 51

Other funds holding ALNY

Sphera Funds Management's ALNY Position: Q2 2026 in Review

Sphera Funds Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 10,800 shares worth $3.25M. The stake represents 0.42% of the portfolio and ranks #77 among its holdings. This is a return to the name: Sphera Funds Management previously reported a position in ALNY as recently as Q3 2024.

Sphera Funds Management first reported a position in ALNY in Q2 2015 and has held it in 13 quarters since. The position peaked at $19.2M in Q2 2018. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Sphera Funds Management held 10,800 shares of Alnylam Pharmaceuticals worth $3.25M as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Sphera Funds Management position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.42% of Sphera Funds Management's portfolio in Q2 2026, its #77 holding.
  • Sphera Funds Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 13 quarters since.
  • Sphera Funds Management's Alnylam Pharmaceuticals position peaked at $19.2M in Q2 2018.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.